A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colitis (UC)
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms Precision-UC
- Sponsors Tillotts Pharma
- 10 Jun 2017 Biomarkers information updated
- 21 Nov 2016 Status changed from active, no longer recruiting to completed.
- 22 Jul 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.